A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).
Abai Xu(Zhujiang Hospital), Chunxiao Liu(Northeast Electric Power University), Ning Jiang(Zhujiang Hospital), Peng Xu(Zhujiang Hospital), Manming Cao(Zhujiang Hospital), Zhe Liu(City University of Hong Kong), Enguang Bi(Zhujiang Hospital), Binshen Chen(Zhujiang Hospital), Chunxiao Chen(Jinan University)
Cited by 1
Related Papers
LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment
|Nature Communications|2018|525
Induction of DNA Fragmentation After 10 to 120 Minutes of Focal Cerebral Ischemia in Rats
|Stroke|1995|275
Ultrastructural and light microscopic evidence of apoptosis after middle cerebral artery occlusion in the rat.
|PubMed|1995|260
Long noncoding RNA BLACAT2 promotes bladder cancer–associated lymphangiogenesis and lymphatic metastasis
|Journal of Clinical Investigation|2018|249
OPTIMAL COMBINATIONS OF SYSTEMATIC SEXTANT AND LATERALLY DIRECTED BIOPSIES FOR THE DETECTION OF PROSTATE CANCER
|The Journal of Urology|2001|231